Business Wire

Shionogi to Present Clinical Data on Lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the Liver (EASL)

Del

Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), announced it will present four posters on lusutrombopag, a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The International Liver Congress, the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 10-14, 2019. Lusutrombopag was granted marketing authorisation by the European Commission (EC) on February 18, 2019 for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing invasive procedures. It has already been approved for use in Japan1 and the US where it is marketed under the brand name Mulpleta®2.

All poster presentations will be displayed in Reed Messe Wien Exhibition & Congress Center Hall B on Saturday, April 13, 2019 from 9:00 am to 5:00 pm Central European Time (CET). The research will be presented in the Cirrhosis and Complications poster area and will include the following:

  • Poster SAT 002: Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing an Invasive Procedure: Pooled Safety Analysis from 3 Studies
    Presenter: Nezam Afdhal
  • Poster SAT 003: Real-World Data Demonstrate Safety and Effectiveness of Lusutrombopag in Chronic Liver Disease Patients with Thrombocytopenia Undergoing Planned Invasive Procedures: Interim Analysis
    Presenter: Nezam Afdhal
  • Poster SAT 006: Efficacy of Oral Thrombopoietin Receptor Agonist Lusutrombopag in Chronic Liver Disease by Underlying Disease Aetiology
    Presenter: Naim Alkhouri
  • Poster SAT 038: Lusutrombopag for Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Who Are Undergoing Planned Invasive Procedures: Pooled Safety Analysis of Bleeding-Related Adverse Events
    Presenter: Edoardo G. Giannini

About Thrombocytopenia in Chronic Liver Disease
Thrombocytopenia is defined as a platelet count of less than 150,000/µL. CLD-associated thrombocytopenia may be caused by multiple factors including splenic sequestration and decreased production of TPO. It is the most common hematologic complication of CLD3,4,5, with studies suggesting that it occurs in up to 78% of patients with cirrhosis.6 Severe thrombocytopenia (platelet count of less than 50,000/µL) is less common, occurring in up to 11% of patients.7 Patients with CLD and thrombocytopenia are at increased risk for bleeding, requiring recurrent platelet transfusions, increased ambulatory visits and inpatient hospital stays compared with patients with CLD without thrombocytopenia.7,8 There is evidence that the annual health care cost of a CLD patient with thrombocytopenia is more than three times that of a CLD patient without thrombocytopenia.8 In addition to the potential of thrombocytopenia, especially severe thrombocytopenia (platelet count less than 50,000/µL), which increases surgical or traumatic bleeding, it may also significantly complicate routine diagnostic procedures and patient care, such as liver biopsy and medically indicated or scheduled procedures for cirrhotic patients, resulting in delayed or cancelled curative treatment.9

About lusutrombopag
Lusutrombopag is a once-daily, orally administered, small molecule TPO receptor agonist that triggers the production of endogenous platelets by interacting with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.

On February 18, 2019, lusutrombopag received marketing authorisation by the EC for the treatment of severe thrombocytopenia in adult patients with CLD undergoing invasive procedures. Prior to this, lusutrombopag was approved by the Ministry of Health, Labour and Welfare in Japan in September 2015 for the improvement of thrombocytopenia associated with CLD in patients undergoing an elective invasive procedure, and by the U.S. Food and Drug Administration (FDA) on July 31, 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. It is currently being commercialised in Japan and the US, where it is marketed under the brand name Mulpleta®.

About Shionogi
Shionogi & Co., Ltd. (“Shionogi”) is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For more information on Shionogi, please visit www.shionogi.co.jp/en/.

Forward Looking Statement
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

References:
1. Japanese Approval of Lusutrombopag. Available at: http://www.info.pmda.go.jp/go/pack/3399010F1022_1_02/ . Last accessed April 2019
2. FDA New Drug Application Approval Letter. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000Approv.pdf . Last accessed April 2019
3. Giannini EG. Aliment Pharmacol Ther. 2006; 23(8):1055-1065.
4. Koruk M, et al. Hepatogastroenterology. 2002; 49(48):1645-1648.
5. Aref S, et al. Hematology. 2004; 9(5/6):351-356.
6. Peck-Radosavljevic M. Liver Int. 2017; 37(6):778-793.
7. de Gottardi, A. et al. Clin Gastroenterol Hepatol. 2009;7(8):906-9
8. Poordad F, et al. J Med Econ. 2012; 15:112-124.
9. Hayashi H, et al. World J Gastroenterol. 2014; 20: 2595-2605.

Lusutrombopag Summary of Product Characteristics is available at: https://www.ema.europa.eu/en/documents/product-information/lusutrombopag-shionogi-epar-product-information_en.pdf

Contact information

Corporate Communications, Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885

Shionogi Inc. U.S. Media Contact
Barbara Kalavik
Telephone: +001973-307-3373

Shionogi Europe Media Contact
Dr. Mark Hill
Telephone: +44-7387-104-907

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Nordson EFD Introduces the Contact versus Jet Dispensing White Paper25.4.2019 12:16:00 CESTPressemelding

Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is pleased to introduce its Contact vs. Jet Dispensing white paper. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005027/en/ As products continue to get smaller and smaller, Nordson EFD has developed new solutions to address this growing need to apply precise, repeatable micro-deposits of assembly fluids in production processes worldwide. “We understand the challenges manufacturers face when their process requires bonding tiny substrates and components together,” said Peter Langer, Business Unit Director of Valves at Nordson EFD. “The deposit tolerance requirements are considerable. And there are a number of variables to consider in order to choose the right dispensing method.” This white paper helps manufacturers understand the difference between two of the most common dispensing methods. Contact dispe

Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe25.4.2019 12:15:00 CESTPressemelding

Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005180/en/ Trident® HD Specimen Radiography System (Photo: Business Wire) The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. The new Trident HD system, which recently received FDA clearance in the US and a CE Mark in Europe, also features a bigger detector that allows for complete imaging of larger breast surgical specimens, along with a wide range of surgical and biopsy sa

Velodyne Lidar, Nikon Announce Manufacturing Agreement for Mass Production of Velodyne Lidar Sensors25.4.2019 12:00:00 CESTPressemelding

Velodyne Lidar, Inc. today announced an agreement with Nikon Corporation, under which Sendai Nikon Corporation, a Nikon subsidiary, will manufacture lidar sensors for Velodyne with plans to start mass production in the second half of 2019. The partnership cements Velodyne’s manufacturing plan and expands its lead in the global lidar sensor market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005236/en/ Velodyne provides the smartest, most powerful lidar solutions for vehicle autonomy and driver assistance. (Photo: Business Wire) “Mass production of our high-performance lidar sensors is key to advancing Velodyne’s immediate plans to expand sales in North America, Europe, and Asia,” said Marta Hall, President and CBDO, Velodyne Lidar. “With this partnership, Velodyne affirms its leadership role in designing, producing, and selling lidar for worldwide implementation. For years, Velodyne has been perfecting lidar technol

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)25.4.2019 12:00:00 CESTPressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH. In the study of 802 enrolled and dosed patients, 9.3 percent of patients treated with selonsertib 18 mg (p=0.42 versus placebo) and 12.1 percent of patients treated with selonsertib 6 mg (p=0.93) achieved a ≥ 1-stage improvement in fibrosis according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment, versus 13.2 percent with placebo. Selonsertib was generally well tolerated and safety results were consistent with prior studies. “While we

Forter Readies Merchants with Launch of PSD2-Compliant Solution25.4.2019 11:25:00 CESTPressemelding

Forter, the leading e-commerce fraud prevention company, today launches its PSD2-compliant merchant offering, Forter PSD2 Solution for Merchants . The comprehensive, payment processor-agnostic solution enables merchants to dynamically route customers to the path of least friction required, prevent all types of fraud and violations of business policies, and optimise the customer’s payment experience – all while meeting full PSD2 compliance. As of 14 September 2019, the revised Payment Services Directive (PSD2) introduces the requirement for merchants to authenticate online transactions within the European Economic Area using Strong Customer Authentication (SCA). Under SCA, merchants have to introduce additional friction into the purchasing process for customers, which will lead to increased drop-off rates, reduce overall conversion rates, and provide a poor customer experience. These changes could ultimately hurt revenue, so merchants must mitigate these challenges and minimise the impa

The Smarter E Europe – Explore Sector Coupling for Yourself at Europe’s Largest Platform for the Energy Industry25.4.2019 09:53:00 CESTPressemelding

The innovation hub The smarter E Europe, encompassing the exhibitions Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power, was launched in 2018 and has seen impressive growth ever since. It will be held for the second time from May 15–17, 2019 at Messe München and will now cover 10 exhibition halls, making it Europe’s largest energy industry event. This growth is due in large part to the upward trend in renewable energies. Since 2010, the proportion of energy generated worldwide from renewable sources has risen from 20 to 25 percent. By 2030, we’re looking at a jump to around 60 percent. In Germany, an average of 45 percent of all electricity generated already came from renewables in the first quarter of 2019. This dynamism is stimulating innovation and shaping the modern energy industry. The buzzword of the hour is sector coupling – a unification of the previously independent electricity, heating and transportation sectors. For instance, a photovoltaic (PV) installation in